Ginger Moore
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ginger Moore has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Tyler J. Wildes
University of Florida Brain Tumor Immunotherapy Program, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, McKnight Brain Institute, University of Florida, Gainesville, Florida
8 shared publications Brandon Wummer
7 shared publicationsChanglin Yang
7 shared publications- Duane A. Mitchell
University of Florida Brain Tumor Immunotherapy Program, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA
7 shared publications - Adam Grippin
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
6 shared publications Bayli DiVita Dean
6 shared publications
Latest Publications
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas
Purpose:Immunotherapy has been demonstrably effective against multiple cancers, yet tumor escape is common. It remains unclear how brain tumors escape immunotherapy and how to overcome this immune escape.Experimental Design:We studied KR158B-luc glioma-bearing mice during treatment with adoptive cellular therapy (ACT) with polyclonal tumor-specific T cells. We tested the immunogenicity of primary and escaped tumors using T-cell restimulation assays. We used flow cytometry and RNA profiling of whole tumors to further define escape mechanisms. To treat immune-escaped tumors, we generated escape variant-specific T cells through the use of escape variant total tumor RNA and administered these cells as ACT. In addition, programmed cell death protein-1 (PD-1) checkpoint blockade was studied in combination with ACT.Results:Escape mechanisms included a shift in immunogenic tumor antigens, downregulation of MHC class I, and upregulation of checkpoint molecules. Polyclonal T cells specific for escape variants displayed greater recognition of escaped tumors than primary tumors. When administered as ACT, these T cells prolonged median survival of escape variant-bearing mice by 60%. The rational combination of ACT with PD-1 blockade prolonged median survival of escape variant glioma-bearing mice by 110% and was dependent upon natural killer cells and T cells.Conclusions:These findings suggest that the immune landscape of brain tumors are markedly different postimmunotherapy yet can still be targeted with immunotherapy.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas
Purpose:Immunotherapy has been demonstrably effective against multiple cancers, yet tumor escape is common. It remains unclear how brain tumors escape immunotherapy and how to overcome this immune escape.Experimental Design:We studied KR158B-luc glioma-bearing mice during treatment with adoptive cellular therapy (ACT) with polyclonal tumor-specific T cells. We tested the immunogenicity of primary and escaped tumors using T-cell restimulation assays. We used flow cytometry and RNA profiling of whole tumors to further define escape mechanisms. To treat immune-escaped tumors, we generated escape variant-specific T cells through the use of escape variant total tumor RNA and administered these cells as ACT. In addition, programmed cell death protein-1 (PD-1) checkpoint blockade was studied in combination with ACT.Results:Escape mechanisms included a shift in immunogenic tumor antigens, downregulation of MHC class I, and upregulation of checkpoint molecules. Polyclonal T cells specific for escape variants displayed greater recognition of escaped tumors than primary tumors. When administered as ACT, these T cells prolonged median survival of escape variant-bearing mice by 60%. The rational combination of ACT with PD-1 blockade prolonged median survival of escape variant glioma-bearing mice by 110% and was dependent upon natural killer cells and T cells.Conclusions:These findings suggest that the immune landscape of brain tumors are markedly different postimmunotherapy yet can still be targeted with immunotherapy.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas
Purpose:Immunotherapy has been demonstrably effective against multiple cancers, yet tumor escape is common. It remains unclear how brain tumors escape immunotherapy and how to overcome this immune escape.Experimental Design:We studied KR158B-luc glioma-bearing mice during treatment with adoptive cellular therapy (ACT) with polyclonal tumor-specific T cells. We tested the immunogenicity of primary and escaped tumors using T-cell restimulation assays. We used flow cytometry and RNA profiling of whole tumors to further define escape mechanisms. To treat immune-escaped tumors, we generated escape variant-specific T cells through the use of escape variant total tumor RNA and administered these cells as ACT. In addition, programmed cell death protein-1 (PD-1) checkpoint blockade was studied in combination with ACT.Results:Escape mechanisms included a shift in immunogenic tumor antigens, downregulation of MHC class I, and upregulation of checkpoint molecules. Polyclonal T cells specific for escape variants displayed greater recognition of escaped tumors than primary tumors. When administered as ACT, these T cells prolonged median survival of escape variant-bearing mice by 60%. The rational combination of ACT with PD-1 blockade prolonged median survival of escape variant glioma-bearing mice by 110% and was dependent upon natural killer cells and T cells.Conclusions:These findings suggest that the immune landscape of brain tumors are markedly different postimmunotherapy yet can still be targeted with immunotherapy.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas
Purpose:Immunotherapy has been demonstrably effective against multiple cancers, yet tumor escape is common. It remains unclear how brain tumors escape immunotherapy and how to overcome this immune escape.Experimental Design:We studied KR158B-luc glioma-bearing mice during treatment with adoptive cellular therapy (ACT) with polyclonal tumor-specific T cells. We tested the immunogenicity of primary and escaped tumors using T-cell restimulation assays. We used flow cytometry and RNA profiling of whole tumors to further define escape mechanisms. To treat immune-escaped tumors, we generated escape variant-specific T cells through the use of escape variant total tumor RNA and administered these cells as ACT. In addition, programmed cell death protein-1 (PD-1) checkpoint blockade was studied in combination with ACT.Results:Escape mechanisms included a shift in immunogenic tumor antigens, downregulation of MHC class I, and upregulation of checkpoint molecules. Polyclonal T cells specific for escape variants displayed greater recognition of escaped tumors than primary tumors. When administered as ACT, these T cells prolonged median survival of escape variant-bearing mice by 60%. The rational combination of ACT with PD-1 blockade prolonged median survival of escape variant glioma-bearing mice by 110% and was dependent upon natural killer cells and T cells.Conclusions:These findings suggest that the immune landscape of brain tumors are markedly different postimmunotherapy yet can still be targeted with immunotherapy.
- Open Access
- 11 August 2020
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (21) , 5689-5700
Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas
Purpose: Immunotherapy has been demonstrably effective against multiple cancers, yet tumor escape is common. It remains unclear how brain tumors escape immunotherapy and how to overcome this immune escape. Experimental Design: We studied KR158B-luc glioma-bearing mice during treatment with adoptive cellular therapy (ACT) with polyclonal tumor-specific T cells. We tested the immunogenicity of primary and escaped tumors using T-cell restimulation assays. We used flow cytometry and RNA profiling of whole tumors to further define escape mechanisms. To treat immune-escaped tumors, we generated escape variant-specific T cells through the use of escape variant total tumor RNA and administered these cells as ACT. In addition, programmed cell death protein-1 (PD-1) checkpoint blockade was studied in combination with ACT. Results: Escape mechanisms included a shift in immunogenic tumor antigens, downregulation of MHC class I, and upregulation of checkpoint molecules. Polyclonal T cells specific for escape variants displayed greater recognition of escaped tumors than primary tumors. When administered as ACT, these T cells prolonged median survival of escape variant-bearing mice by 60%. The rational combination of ACT with PD-1 blockade prolonged median survival of escape variant glioma-bearing mice by 110% and was dependent upon natural killer cells and T cells. Conclusions: These findings suggest that the immune landscape of brain tumors are markedly different postimmunotherapy yet can still be targeted with immunotherapy.
- 11 August 2020
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (21) , 5689-5700
Open AccessImmune Escape After Adoptive T-cell Therapy for Malignant Gliomas
Purpose: Immunotherapy has been demonstrably effective against multiple cancers, yet tumor escape is common. It remains unclear how brain tumors escape immunotherapy and how to overcome this immune escape. Experimental Design: We studied KR158B-luc glioma-bearing mice during treatment with adoptive cellular therapy (ACT) with polyclonal tumor-specific T cells. We tested the immunogenicity of primary and escaped tumors using T-cell restimulation assays. We used flow cytometry and RNA profiling of whole tumors to further define escape mechanisms. To treat immune-escaped tumors, we generated escape variant-specific T cells through the use of escape variant total tumor RNA and administered these cells as ACT. In addition, programmed cell death protein-1 (PD-1) checkpoint blockade was studied in combination with ACT. Results: Escape mechanisms included a shift in immunogenic tumor antigens, downregulation of MHC class I, and upregulation of checkpoint molecules. Polyclonal T cells specific for escape variants displayed greater recognition of escaped tumors than primary tumors. When administered as ACT, these T cells prolonged median survival of escape variant-bearing mice by 60%. The rational combination of ACT with PD-1 blockade prolonged median survival of escape variant glioma-bearing mice by 110% and was dependent upon natural killer cells and T cells. Conclusions: These findings suggest that the immune landscape of brain tumors are markedly different postimmunotherapy yet can still be targeted with immunotherapy.
- 11 November 2019
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 21 (Supplement) , vi253-vi254
TMIC-29. METABOLIC INTERACTIONS BETWEEN TREATMENT-RESISTANT SLOW-CYCLING CELLS AND THE IMMUNE SYSTEM IN HIGH-GRADE GLIOMA
INTRODUCTION: Intratumoral heterogeneity is increasingly recognized as a determinant of therapy resistance and disease recurrence; this is exemplified by glioblastoma (GBM), one of the most lethal malignancies. We recently revealed that GBM contain cell subpopulations with distinct metabolic requirements, with fast-cycling cells (FCCs) harnessing aerobic glycolysis, and treatment-resistant slow-cycling cells (SCCs) preferentially engaging lipid metabolism. How the different tumor cell populations interact with immune cells and how this metabolic heterogeneity shapes the immune landscape in GBM has yet to be understood. OBJECTIVES: The objectives of this study are to understand the mechanisms of communication in the tumor microenvironment, specifically to characterize the metabolic interactions between SCCs (a therapeutically resistant population of cancer cells that drive disease progression and recurrence) and the immune compartment. METHODS: The murine glioma cell line KR158 (derived from a Nf1;Trp53 mutant mouse) was used to establish the slow-cycling cell paradigm and metabolic heterogeneity in an immune-competent model of glioma. RESULTS: Similar to what we observed in patient-derived specimens, mouse KR158-derived SCCs demonstrate tumorigenicity, treatment resistance and up-regulation of stemness programs and lipid metabolic pathways. We determined that tumor progression is regulated by the interaction of SCCs with the immune system and established that these cells are driving a pro-tumorigenic microenvironment via the recruitment of immune suppressive myeloid cells. Importantly, the immune microenvironment shaped by SCCs is marked by specific metabolic features showing enhanced lipid exchange capacities that we propose are exploited by SCCs to support their survival and functions. CONCLUSION: Our study indicates that SCCs play a pivotal role in shifting the GBM milieu toward an immune regulatory phenotype but importantly reveals an unprecedented metabolic cooperation, which represents a novel therapeutic target to antagonize GBM.
- 11 November 2019
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 21 (Supplement) , vi253-vi254
TMIC-29. METABOLIC INTERACTIONS BETWEEN TREATMENT-RESISTANT SLOW-CYCLING CELLS AND THE IMMUNE SYSTEM IN HIGH-GRADE GLIOMA
INTRODUCTION: Intratumoral heterogeneity is increasingly recognized as a determinant of therapy resistance and disease recurrence; this is exemplified by glioblastoma (GBM), one of the most lethal malignancies. We recently revealed that GBM contain cell subpopulations with distinct metabolic requirements, with fast-cycling cells (FCCs) harnessing aerobic glycolysis, and treatment-resistant slow-cycling cells (SCCs) preferentially engaging lipid metabolism. How the different tumor cell populations interact with immune cells and how this metabolic heterogeneity shapes the immune landscape in GBM has yet to be understood. OBJECTIVES: The objectives of this study are to understand the mechanisms of communication in the tumor microenvironment, specifically to characterize the metabolic interactions between SCCs (a therapeutically resistant population of cancer cells that drive disease progression and recurrence) and the immune compartment. METHODS: The murine glioma cell line KR158 (derived from a Nf1;Trp53 mutant mouse) was used to establish the slow-cycling cell paradigm and metabolic heterogeneity in an immune-competent model of glioma. RESULTS: Similar to what we observed in patient-derived specimens, mouse KR158-derived SCCs demonstrate tumorigenicity, treatment resistance and up-regulation of stemness programs and lipid metabolic pathways. We determined that tumor progression is regulated by the interaction of SCCs with the immune system and established that these cells are driving a pro-tumorigenic microenvironment via the recruitment of immune suppressive myeloid cells. Importantly, the immune microenvironment shaped by SCCs is marked by specific metabolic features showing enhanced lipid exchange capacities that we propose are exploited by SCCs to support their survival and functions. CONCLUSION: Our study indicates that SCCs play a pivotal role in shifting the GBM milieu toward an immune regulatory phenotype but importantly reveals an unprecedented metabolic cooperation, which represents a novel therapeutic target to antagonize GBM.
- 11 November 2019
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 21 (Supplement) , vi129
IMMU-49. THE SELECTIVE ENRICHMENT OF T CELLS TARGETING UNKNOWN BRAIN CANCER ANTIGENS VIA TROGOCYTOSIS
INTRODUCTION: Trogocytosis is the exchange of membrane components from one cell to another. During T cell activation, dendritic cell (DC) and T cell membranes become anchored around the TCR/MHC complex and their costimulatory molecules. Part of the DC membrane is pulled away, taken in, and educates the T cell to recognize foreign antigens. We have utilized this phenomenon to isolate and expand a select population of T cells that have undergone this interaction. HYPOTHESIS: (1) By selecting for cells that have undergone trogocytosis, we are enriching for a tumor-specific population of T cells and can improve anti-tumor responses in the setting of adoptive cellular transfer (ACT). (2) This approach represents a reliable method to detect tumor-specific antigens across numerous types of brain cancers. METHODS: Murine DCs are pulsed with KR158B glioma RNA and then stained with a proliferation dye such as Cell Trace Violet. These cells are co-cultured overnight with CD3+ splenocytes of vaccinated mice and IL-2. The cells are then sorted into T cells that have undergone trogocytosis (CD3+ CTV+) and those that have not (CD3+CTV-) and placed back into co-culture with fresh dendritic cells for expansion of tumor-specific T cells and/or restimulation assay. Additionally, T cells are spectratyped and phenotyped by flow cytometry. RESULTS: Cells that had undergone trogocytosis (CD3+CTV+) demonstrated superior IFNγ secretion and enriched for CD4+ and CD8+ central memory and effector subsets compared to cells that had not undergone trogocytosis (CD3+CTV-). Spectratyping analysis revealed CD3+CTV+ cells enriched for Vβ 5.1/5.2 and Vβ 6, two families we have determined to be crucial for anti-tumor efficacy. CONCLUSIONS: This method of selection and enrichment of tumor-specific T cells has promising implications for the enhancement of ACT. This method can be used to elucidate tumor-specific antigens that are unique to an individual’s cancer fingerprint.
- 11 November 2019
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 21 (Supplement) , vi129
IMMU-49. THE SELECTIVE ENRICHMENT OF T CELLS TARGETING UNKNOWN BRAIN CANCER ANTIGENS VIA TROGOCYTOSIS
INTRODUCTION: Trogocytosis is the exchange of membrane components from one cell to another. During T cell activation, dendritic cell (DC) and T cell membranes become anchored around the TCR/MHC complex and their costimulatory molecules. Part of the DC membrane is pulled away, taken in, and educates the T cell to recognize foreign antigens. We have utilized this phenomenon to isolate and expand a select population of T cells that have undergone this interaction. HYPOTHESIS: (1) By selecting for cells that have undergone trogocytosis, we are enriching for a tumor-specific population of T cells and can improve anti-tumor responses in the setting of adoptive cellular transfer (ACT). (2) This approach represents a reliable method to detect tumor-specific antigens across numerous types of brain cancers. METHODS: Murine DCs are pulsed with KR158B glioma RNA and then stained with a proliferation dye such as Cell Trace Violet. These cells are co-cultured overnight with CD3+ splenocytes of vaccinated mice and IL-2. The cells are then sorted into T cells that have undergone trogocytosis (CD3+ CTV+) and those that have not (CD3+CTV-) and placed back into co-culture with fresh dendritic cells for expansion of tumor-specific T cells and/or restimulation assay. Additionally, T cells are spectratyped and phenotyped by flow cytometry. RESULTS: Cells that had undergone trogocytosis (CD3+CTV+) demonstrated superior IFNγ secretion and enriched for CD4+ and CD8+ central memory and effector subsets compared to cells that had not undergone trogocytosis (CD3+CTV-). Spectratyping analysis revealed CD3+CTV+ cells enriched for Vβ 5.1/5.2 and Vβ 6, two families we have determined to be crucial for anti-tumor efficacy. CONCLUSIONS: This method of selection and enrichment of tumor-specific T cells has promising implications for the enhancement of ACT. This method can be used to elucidate tumor-specific antigens that are unique to an individual’s cancer fingerprint.
- Open Access
- 1 November 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (11) , eaav9879
Massive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy
Extensive clonal T cell expansion is associated with response to immunotherapy.
- 1 November 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (11) , eaav9879
Open AccessMassive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy
Extensive clonal T cell expansion is associated with response to immunotherapy.
- Open Access
- 10 July 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-9
Quantitative characterization of 3D bioprinted structural elements under cell generated forces
With improving biofabrication technology, 3D bioprinted constructs increasingly resemble real tissues. However, the fundamental principles describing how cell-generated forces within these constructs drive deformations, mechanical instabilities, and structural failures have not been established, even for basic biofabricated building blocks. Here we investigate mechanical behaviours of 3D printed microbeams made from living cells and extracellular matrix, bioprinting these simple structural elements into a 3D culture medium made from packed microgels, creating a mechanically controlled environment that allows the beams to evolve under cell-generated forces. By varying the properties of the beams and the surrounding microgel medium, we explore the mechanical behaviours exhibited by these structures. We observe buckling, axial contraction, failure, and total static stability, and we develop mechanical models of cell-ECM microbeam mechanics. We envision these models and their generalizations to other fundamental 3D shapes to facilitate the predictable design of biofabricated structures using simple building blocks in the future.
- 10 July 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-9
Open AccessQuantitative characterization of 3D bioprinted structural elements under cell generated forces
With improving biofabrication technology, 3D bioprinted constructs increasingly resemble real tissues. However, the fundamental principles describing how cell-generated forces within these constructs drive deformations, mechanical instabilities, and structural failures have not been established, even for basic biofabricated building blocks. Here we investigate mechanical behaviours of 3D printed microbeams made from living cells and extracellular matrix, bioprinting these simple structural elements into a 3D culture medium made from packed microgels, creating a mechanically controlled environment that allows the beams to evolve under cell-generated forces. By varying the properties of the beams and the surrounding microgel medium, we explore the mechanical behaviours exhibited by these structures. We observe buckling, axial contraction, failure, and total static stability, and we develop mechanical models of cell-ECM microbeam mechanics. We envision these models and their generalizations to other fundamental 3D shapes to facilitate the predictable design of biofabricated structures using simple building blocks in the future.
- 23 April 2019
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 21 (Supplement) , ii67
BSTM-03. INCREASING ANTI-TUMOR T CELL ACTIVATION, VELOCITY, AND MIGRATION TO BRAIN STEM GLIOMA USING HEMATOPOIETIC STEM AND PROGENITOR CELLS
INTRODUCTION: The survival benefit of adoptive cellular therapy is significantly enhanced by concomitant transfer of bone marrow derived hematopoietic stem cells (HSC) with tumor-reactive T cells in two preclinical models of brain stem glioma (BSG), OB1 (wildtype H3.3), and K2 (H3.3K27M mutation). Using a novel method of 3D printing to fabricate microtumors using BSG cells, we interrogate tumor microenvironment and directly demonstrate that the presence of HSC-derived cells in the microenvironment increases T cell velocity and migration to tumor, and increased tumor cell death. In addition, longitudinal studies in a 3D system allows us to determine properties of tumor cells that escape T cell killing, and differences between T cells that infiltrate tumor bed and those that remain in the peritumoral area. METHODS: We employ an in vitro system using of BSG cells that are 3D printed into a liquid-like solid. Tumor-reactive T cells are generated against BSG cells and printed at distances from the 3D tumoroid to allow migration and T cell patterning studies. Cells retain function and viability in this system for greater than 30 days. Gene expression is used to validate cell properties. RESULTS: We found that HSCs are required for T cell infiltration to orthotopic brain stem glioma in vivo. In our in vitro 3D models of BSG, tumor-reactive T cell velocity of migration and infiltration was significantly increased in the presence of HSCs. Interrogation of T cells that remained adjacent to tumor but did not infiltrate revealed down regulation of chemokines required for migration. In the meantime, tumor cells that escaped T cell killing showed downregulation of MHC-I molecules on their cell surface. These studies are unique in that we are capable of studying biological properties of tumor-reactive T cells that are challenging in vivo.
- 23 April 2019
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 21 (Supplement) , ii67
BSTM-03. INCREASING ANTI-TUMOR T CELL ACTIVATION, VELOCITY, AND MIGRATION TO BRAIN STEM GLIOMA USING HEMATOPOIETIC STEM AND PROGENITOR CELLS
INTRODUCTION: The survival benefit of adoptive cellular therapy is significantly enhanced by concomitant transfer of bone marrow derived hematopoietic stem cells (HSC) with tumor-reactive T cells in two preclinical models of brain stem glioma (BSG), OB1 (wildtype H3.3), and K2 (H3.3K27M mutation). Using a novel method of 3D printing to fabricate microtumors using BSG cells, we interrogate tumor microenvironment and directly demonstrate that the presence of HSC-derived cells in the microenvironment increases T cell velocity and migration to tumor, and increased tumor cell death. In addition, longitudinal studies in a 3D system allows us to determine properties of tumor cells that escape T cell killing, and differences between T cells that infiltrate tumor bed and those that remain in the peritumoral area. METHODS: We employ an in vitro system using of BSG cells that are 3D printed into a liquid-like solid. Tumor-reactive T cells are generated against BSG cells and printed at distances from the 3D tumoroid to allow migration and T cell patterning studies. Cells retain function and viability in this system for greater than 30 days. Gene expression is used to validate cell properties. RESULTS: We found that HSCs are required for T cell infiltration to orthotopic brain stem glioma in vivo. In our in vitro 3D models of BSG, tumor-reactive T cell velocity of migration and infiltration was significantly increased in the presence of HSCs. Interrogation of T cells that remained adjacent to tumor but did not infiltrate revealed down regulation of chemokines required for migration. In the meantime, tumor cells that escaped T cell killing showed downregulation of MHC-I molecules on their cell surface. These studies are unique in that we are capable of studying biological properties of tumor-reactive T cells that are challenging in vivo.